By Fineline Cube Shanghai Yizhong Pharmaceutical Co., Ltd (SHA: 688091) announced that the Investigational New Drug (IND) application for its self‑developed innovative drug YXC‑002, targeting non‑small cell lung cancer (NSCLC), has been officially approved, clearing the way for clinical trials of a next‑generation therapy designed to address key resistance and brain‑metastasis challenges in EGFR‑driven disease.
IND Approval Summary
| Item | Detail |
|---|---|
| Company | Shanghai Yizhong Pharmaceutical Co., Ltd (SHA: 688091) |
| Product | YXC‑002 (self‑developed innovative drug) |
| Drug Class | Fourth‑generation, highly brain‑penetrant EGFR‑TKI |
| Indication | Non‑small cell lung cancer (NSCLC) |
| Regulatory Status | IND officially approved |
| Intellectual Property | Proprietary IP, independently developed |
| Announcement Date | 19 Aug 2026 |
Drug Profile – YXC‑002
- Class: Novel small‑molecule candidate, a fourth‑generation EGFR‑TKI with a unique and innovative molecular design and clear pharmacological mechanisms
- Target Spectrum: A range of classic and non‑classic EGFR driver mutations and resistance mutations in NSCLC
- CNS Coverage: Effectively addresses treatment of patients with central nervous system (CNS) metastases
Differentiation – Three Key Advantages
Overcomes Resistance
- Overcomes treatment failure caused by the C797S resistance point mutation seen in earlier‑generation EGFR inhibitors
- Maintains high selectivity for wild‑type EGFR, resulting in lower wild‑type EGFR‑related toxicity
Superior Anti‑Tumor Efficacy
- Compared to BDTX‑1535, a novel fourth‑generation EGFR inhibitor currently in Phase II clinical trials, YXC‑002 demonstrates superior anti‑tumor efficacy
- Particularly pronounced against sensitizing mutations (19del) and triple mutations (L858R‑T790M‑C797S)
Enhanced CNS Penetration
- Its unique chemical structure enables enhanced penetration across the blood‑brain barrier, a critical advantage given the high incidence of CNS metastases in EGFR‑mutant NSCLC
Market Impact & Outlook
- Crowded but High‑Stakes Market: EGFR‑mutant NSCLC is one of the largest targeted‑therapy segments in China, with resistance to third‑generation TKIs (e.g., after C797S emergence) creating a clear opening for fourth‑generation agents.
- CNS Metastasis Unmet Need: Brain metastases are a leading cause of treatment failure in EGFR‑mutant NSCLC; YXC‑002’s brain‑penetrant design positions it where many competitors struggle.
- Competitive Benchmarking: The direct preclinical comparison to BDTX‑1535, the most advanced fourth‑generation EGFR inhibitor, signals YXC‑002’s ambition to compete head‑to‑head in this emerging drug class — pending clinical confirmation.
- Watch Items: First‑in‑human trial design and enrollment, early safety and efficacy readouts (particularly in C797S‑mutant and CNS‑metastatic cohorts), and potential partnering interest from larger oncology players.
Forward-Looking Statements
This brief contains forward‑looking statements regarding clinical development, regulatory outcomes, and commercial expectations for YXC‑002. Actual results may differ due to risks including early‑stage clinical uncertainty, regulatory decisions, and competitive dynamics in EGFR‑mutant NSCLC.-Fineline Info & Tech